Antibacterial Drugs Market By Drug Type (Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones, Macrolides, Phenicols, Miscellaneous) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

This report on the global antibacterial drug market studies various drug classes used for treating bacterial infections and pipeline analysis of upcoming potential drugs. Bacterial infection, irrespective of its etiology, is an important concern in patients with cirrhosis since it is associated with increased morbidity and mortality. According to the World Health Organization (WHO), cirrhotic patients from developed countries indicate urinary tract infections (12–29%) to be the most frequent cause of bacterial sepsis, followed by spontaneous bacterial peritonitis (15–23%), respiratory tract infection (6–10%), and bacteremia (4–9%).

The various drug classes studied for this study include aminoglycosides, beta-lactams, tetracyclines, sulfonamides, quinolones, macrolides, phenicols, and miscellaneous antibacterials. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn, along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for the antibacterial drug market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are solithromycin (Cempra, Inc.), VivaGel/SPL7013 (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.), and others. In addition, the report also has information about the drugs in phases II and I of the clinical trials from a qualitative point of view.

The geographic segmentation of the global antibacterial drugs market is performed for North America, Europe, Asia-Pacific, and the rest of the world markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn and the respective CAGRs for 2016 to 2022, considering 2015 as the base year.

According to market stakeholders, bacterial infections cause an enormous financial and physical burden of disease throughout the globe and kill millions of humans and animals. The few most common bacterial infections are pneumonia, diarrhea and meningitis, genito-urinary infections, and blood infections. Recently hospital acquired diseases such as tuberculosis, pneumonia, and others are on the rise in many parts of the world. Resistance to antibiotics is now widespread among bacteria and is increasing at an alarming rate.

Based on the type of drug class, the antibacterial drugs market is segmented into:

  • Aminoglycosides
  • Beta-Lactams
  • Tetracyclines
  • Sulfonamides
  • Quinolones
  • Macrolides
  • Phenicols
  • Miscellaneous

In 2015, beta-lactams accounted for the largest market share of 55.8% of the global antibacterial drugs market, followed by quinolones. In the near future, these drug classes are expected to experience a decline in their market share during the forecast period 2016 to 2022 because leading brands will lose their market exclusivity, coupled with a high rate of clinical trial failures, rising number of drug resistant bacterial strains and high influx of generic drugs. Thus, based on the factors mentioned above, the global antibacterial drugs market is expected to witness slow growth during the forecast period from 2016 to 2022. Although, the miscellaneous antibacterial drug class is expected to project noticeable growth along with rising demand for novel therapies against bacterial infections and the aging population.

For the purpose of this study, the global antibacterial drug market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Africa's Middle East

In the base year 2015, it was observed that Asia-Pacific dominated the overall market and is also projected to witness the fastest growth during the forecast period 2016-2022. The key factors assisting the growth of the Asia-Pacific antibacterial drugs market are that it accounts for the largest infected population in the world with a variety of bacterial infections such as pneumonia, tuberculosis, and tetanus; the presence of a large number of manufacturers of active pharmaceutical ingredients and generic drugs; high disposable income; a rising geriatric population; and emerging healthcare infrastructure. North America, followed by Europe, is the second-largest antibacterial drug market globally in terms of revenue. However, North America and Europe are expected to have slow growth over the next few years because of strict regulations, shorter product life cycles, and the spread of generics. 

Frequently asked questions :

The market for Antibacterial Drugs is expected to reach US$ XX Bn in 2022.

The Antibacterial Drugs market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2016-2022.

The base year of this report is 2021.

Pfizer Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Johnson & Johnson Limited are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Jun 2016
Category:  Medical Devices
Report ID:   57891
Report Format:   PDF
Pages:   120
Rating:    4.5 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support